ImmunityBio (NASDAQ:IBRX) Given Buy Rating at HC Wainwright
ImmunityBio (NASDAQ:IBRX – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $8.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 218.73% from the stock’s current price. Separately, D. Boral Capital reissued […]
ImmunityBio (NASDAQ:IBRX – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $8.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 218.73% from the stock’s current price. Separately, D. Boral Capital reissued […]
